We have located links that may give you full text access.
Prognosis and management of corneal transplantation for herpetic keratitis.
Archives of Ophthalmology 1980 October
One hundred thirty-two penetrating keratoplasties (91 patients) for herpetic keratoplasty were reviewed retrospectively. The overall survival rate of clear keratoplasties to two years was 64% and to five years was 62%. The significant prognostic factors were preoperative ocular inflammatory status and degree of corneal vascularization. The two-year survival rate of a clear keratoplasty was 69% where eyes were inflamed at the time of surgery, compared with 44% in actively inflamed eyes. Allograft rejection, the major cause of a clouded herpetic keratoplasty, increased in frequency with increasing corneal vascularization. Antiviral cover was not used with routine postoperative steroids or with steroid intensive therapy for rejection. Epithelial herpetic recurrences occurred in 32% of eyes undergoing allograft rejection within four months of initiation of treatment for rejection. This is compared with otherwise uncomplicated keratoplasties where the epithelial recurrence rate was 6% at four months, on high-dose postoperative corticosteroid therapy without antiviral cover.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app